First Time Loading...

Haw Par Corporation Ltd
SGX:H02

Watchlist Manager
Haw Par Corporation Ltd Logo
Haw Par Corporation Ltd
SGX:H02
Watchlist
Price: 9.64 SGD -2.13% Market Closed
Updated: May 4, 2024
Section:
 

Relative Value

The Relative Value of one H02 stock under the Base Case scenario is 6.38 SGD. Compared to the current market price of 9.64 SGD, Haw Par Corporation Ltd is Overvalued by 34%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

H02 Relative Value
Base Case
6.38 SGD
Overvaluation 34%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

9.2
P/S
P/S
Price to Sales
9.2
vs History
92
vs Industry
17
Median 3Y
12.3
Median 5Y
11.2
Industry
2.5
More Details
9.9
P/E
P/E
Price to Earnings
9.9
vs History
96
vs Industry
38
Median 3Y
15.7
Median 5Y
14.1
Industry
23.4
More Details
34
P/OCF
P/OCF
Price to OCF
34
vs History
77
vs Industry
13
Median 3Y
75.8
Median 5Y
51
Industry
17.4
More Details
40.1
P/FCFE
P/FCFE
Price to FCFE
40.1
vs History
87
vs Industry
14
Median 3Y
64.7
Median 5Y
56.2
Industry
23.6
More Details
0.6
P/B
P/B
Price to Book Value
0.6
vs History
87
vs Industry
71
Median 3Y
0.7
Median 5Y
0.8
Industry
2.1
More Details
6.8
EV/S
EV/S
Enterprise Value to Sales
6.8
vs History
87
vs Industry
19
Median 3Y
10.1
Median 5Y
9.6
Industry
2.6
More Details
11.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
11.8
vs History
87
vs Industry
19
Median 3Y
18.6
Median 5Y
17.4
Industry
5.2
More Details
22.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
22.3
vs History
79
vs Industry
17
Median 3Y
37.8
Median 5Y
33.4
Industry
13.7
More Details
24.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
24.3
vs History
77
vs Industry
19
Median 3Y
44.5
Median 5Y
37.1
Industry
17.2
More Details
25.3
EV/OCF
EV/OCF
Enterprise Value to OCF
25.3
vs History
73
vs Industry
19
Median 3Y
54.7
Median 5Y
43.5
Industry
16.2
More Details
28.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
28.9
vs History
73
vs Industry
17
Median 3Y
86.4
Median 5Y
82
Industry
17.8
More Details
0.5
EV/IC
EV/IC
Enterprise Value to IC
0.5
vs History
87
vs Industry
74
Median 3Y
0.6
Median 5Y
0.7
Industry
2
More Details

Multiples Across Competitors

H02 Competitors Multiples
Haw Par Corporation Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SG
Haw Par Corporation Ltd
SGX:H02
2.1B SGD 9.2 9.9 22.3 24.3
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
698.5B USD 19.4 113.8 55.8 63.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.8T DKK 16.3 45.3 33.1 36.1
US
Johnson & Johnson
NYSE:JNJ
359.3B USD 4.2 9.3 11.5 15
US
Merck & Co Inc
NYSE:MRK
322.8B USD 5.3 140 33.3 52.8
UK
AstraZeneca PLC
LSE:AZN
186.8B GBP 5.1 39.4 140.7 225.6
CH
Novartis AG
SIX:NOVN
179.8B CHF 4.3 13.4 9.8 16.2
CH
Roche Holding AG
SIX:ROG
173.2B CHF 3 15.1 8.6 10.2
US
Pfizer Inc
NYSE:PFE
157B USD 2.9 -508.1 12.6 20.1
P/E Multiple
Earnings Growth
SG
Haw Par Corporation Ltd
SGX:H02
Average P/E: 48.3
9.9
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
113.8
346%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
45.3
84%
US
Johnson & Johnson
NYSE:JNJ
9.3
-20%
US
Merck & Co Inc
NYSE:MRK
140
7 454%
UK
AstraZeneca PLC
LSE:AZN
39.4
168%
CH
Novartis AG
SIX:NOVN
13.4
15%
CH
Roche Holding AG
SIX:ROG
15.1
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -508.1
680%

See Also

Summary
H02 intrinsic value, competitors valuation, and company profile.
DCF Valuation
H02 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
H02 stock valuation using valuation multiples.
Wall Street Estimates
H02 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
H02 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 134,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.